NMR-based plant metabolomics: where do we stand, where do we go?

被引:263
|
作者
Kim, Hye Kyong [1 ]
Choi, Young Hae [1 ]
Verpoorte, Robert [1 ]
机构
[1] Leiden Univ, Inst Biol, Sect Metabol, NL-2300 RA Leiden, Netherlands
关键词
MAGNETIC-RESONANCE-SPECTROSCOPY; IONIC LIQUIDS; H-1-NMR SPECTROSCOPY; QUALITY-CONTROL; IDENTIFICATION; CLASSIFICATION; EXTRACTS; METABONOMICS; METABOLITES; RESISTANCE;
D O I
10.1016/j.tibtech.2011.02.001
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
NMR-based metabolomics is an important tool for studying biological systems and has been applied in various organisms, including animals, plants and microbes. NMR is able to provide a 'holistic view' of the metabolites under certain conditions, and thus is advantageous for metabolomic studies. To maximize the use of the information obtained, it is also important to create a platform to measure, store and share data. Public databases for storing and sharing information are still lacking for NMR-based metabolomic analysis in plants. Such databases are urgently needed to make metabolic profiling a real omics technology. In addition, to understand metabolic processes in depth, single-cell analysis and the turnover of metabolites in pathways (fluxomics) should be measured.
引用
收藏
页码:267 / 275
页数:9
相关论文
共 50 条
  • [1] Gephyrin: where do we stand, where do we go?
    Fritschy, Jean-Marc
    Harvey, Robert J.
    Schwarz, Guenter
    TRENDS IN NEUROSCIENCES, 2008, 31 (05) : 257 - 264
  • [2] ColVI myopathies: where do we stand, where do we go?
    Allamand, Valerie
    Brinas, Laura
    Richard, Pascale
    Stojkovic, Tanya
    Quijano-Roy, Susana
    Bonne, Gisele
    SKELETAL MUSCLE, 2011, 1
  • [3] Investigative dermatology: where do we stand and where do we go?
    Maurer, M.
    von Stebut, E.
    EXPERIMENTAL DERMATOLOGY, 2010, 19 (10) : 857 - 857
  • [4] Rye and health - Where do we stand and where do we go?
    Jonsson, Karin
    Andersson, Roger
    Knudsen, Knud Erik Bach
    Hallmans, Goran
    Hanhineva, Kati
    Katina, Kati
    Kolehmainen, Marjukka
    Kyro, Cecilie
    Langton, Maud
    Nordlund, Emilia
    Laerke, Helle Nygaard
    Olsen, Anja
    Poutanen, Kajsa
    Tjonneland, Anne
    Landberg, Rikard
    TRENDS IN FOOD SCIENCE & TECHNOLOGY, 2018, 79 : 78 - 87
  • [5] ColVI myopathies: where do we stand, where do we go?
    Valérie Allamand
    Laura Briñas
    Pascale Richard
    Tanya Stojkovic
    Susana Quijano-Roy
    Gisèle Bonne
    Skeletal Muscle, 1
  • [6] Where do we stand on neuroprotection? Where do we go from here?
    Shoulson, I
    MOVEMENT DISORDERS, 1998, 13 : 46 - 48
  • [7] Treatment of negative symptoms: Where do we stand, and where do we go?
    Aleman, Andre
    Lincoln, Tania M.
    Bruggeman, Richard
    Melle, Ingrid
    Arends, Johan
    Arango, Celso
    Knegtering, Henderikus
    SCHIZOPHRENIA RESEARCH, 2017, 186 : 55 - 62
  • [8] THE CYTOGENETICS OF RENAL TUMORS - WHERE DO WE STAND, WHERE DO WE GO
    WALTER, TA
    BERGER, CS
    SANDBERG, AA
    CANCER GENETICS AND CYTOGENETICS, 1989, 43 (01) : 15 - 34
  • [9] THE DECADE OF TOTAL QUALITY - WHERE DO WE STAND - WHERE DO WE GO
    YEAGER, R
    PIMA MAGAZINE, 1994, 76 (03): : S2 - S3
  • [10] Occupational Rhinitis and Asthma: Where Do We Stand, Where Do We Go?
    Castano, Roberto
    Malo, Jean-Luc
    CURRENT ALLERGY AND ASTHMA REPORTS, 2010, 10 (02) : 135 - 142